Hyperinsulinism is the most common cause of persistent, severe low blood sugar in newborns. The condition occurs when a baby’s pancreas releases too much insulin, driving blood glucose dangerously low and starving the brain of its primary fuel. Some cases are transient, resolving within days, while others are caused by genetic defects that require aggressive medical or surgical treatment. The distinction matters enormously because prolonged untreated hypoglycemia can cause permanent brain damage, yet with timely intervention many of these babies do well.
What Causes Hyperinsulinism in Newborns
The causes fall into two broad categories: transient and persistent. Transient hyperinsulinism is far more common and typically affects babies born to mothers with diabetes, babies who experienced stress during birth, or infants who are large or small for their gestational age. In these cases the overproduction of insulin is a temporary response that usually fades within days to weeks. One striking case report described a full-term infant with severe hyperinsulinism whose mother had no diabetes but had been drinking about two liters of a high-sugar energy drink daily in her final trimester; the baby’s insulin level was more than four times the upper limit of normal, yet the condition resolved by the seventh day of life.1PubMed Central. Neonatal hyperinsulinism secondary to maternal intake of high-sugar drinks
Persistent hyperinsulinism, often called congenital hyperinsulinism, has a genetic basis. The most frequent culprit involves mutations in the genes that build a potassium channel on the surface of insulin-producing beta cells. This channel acts like a switch: when blood sugar rises, the channel closes, triggering insulin release, and when blood sugar drops, the channel opens, shutting off that signal. Mutations that disable or reduce the function of the channel leave insulin secretion essentially stuck in the “on” position regardless of how low glucose falls.2PubMed Central. KATP channel mutations in congenital hyperinsulinism: Progress and challenges towards mechanism-based therapies Most disease-causing mutations in the two genes encoding these channel components are recessively inherited, meaning a baby must inherit a defective copy from each parent, though dominant mutations have also been reported.3The Journal of Clinical Investigation. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations Rarer genetic forms involve mutations in enzymes and receptors related to other steps in the insulin-release pathway, but channel defects remain the predominant genetic cause.
Focal Versus Diffuse Disease
Understanding whether a baby’s hyperinsulinism is focal or diffuse changes the treatment plan dramatically. In the focal form, only a small region of the pancreas is abnormal. This form arises sporadically: the baby inherits a single defective gene copy from one parent and then loses the normal copy in a localized patch of pancreatic tissue during fetal development. In the diffuse form, the entire pancreas is affected, and the condition is inherited in an autosomal recessive or, less commonly, dominant pattern.4PubMed Central. The molecular mechanisms, diagnosis and management of congenital hyperinsulinism
The distinction matters because focal disease can be cured by surgically removing a small piece of the pancreas, while diffuse disease may require removal of most of it, with serious long-term consequences. The two forms look identical in their early presentation: both produce severe hypoglycemia in the first hours or days of life. Telling them apart requires specialized imaging and, in many cases, genetic testing.
Recognizing the Symptoms
Newborns cannot tell you they feel shaky or dizzy. Instead, the signs of dangerously low blood sugar tend to be nonspecific. Parents and clinicians look for poor feeding, jitteriness, a weak or high-pitched cry, lethargy, floppiness, blue or pale skin, and, in more severe episodes, seizures. One case report described a girl admitted for lethargy, irritability, and generalized seizures accompanied by profound hypoglycemia.5PubMed Central. Congenital hyperinsulinsim: case report and review of literature Seizures in particular signal that the brain has been deprived of glucose long enough to cause electrical misfiring, and they should be treated as a medical emergency.
Another clue is how much glucose the baby needs to maintain normal blood sugar levels. Most newborns require a glucose infusion rate of about four to six milligrams per kilogram per minute when they need IV support. A baby with hyperinsulinism often requires far higher rates, sometimes more than fifteen or twenty, because insulin is actively pulling glucose out of the bloodstream.1PubMed Central. Neonatal hyperinsulinism secondary to maternal intake of high-sugar drinks That unusually high glucose demand is itself a diagnostic red flag.
How Hyperinsulinism Is Diagnosed
Diagnosing hyperinsulinism is trickier than it might seem. You would expect the diagnosis to rest on finding an elevated insulin level during a hypoglycemic episode, and sometimes it does. But insulin levels are not always measurably elevated even when the condition is clearly present. The diagnosis often relies instead on indirect markers of too much insulin activity: the body’s failure to switch on its normal backup systems during low blood sugar. When insulin is inappropriately active, the liver cannot release its stored glucose, fat breakdown is suppressed, and ketone production stays low. Finding suppressed free fatty acids and low ketone levels at the time of hypoglycemia, along with a blood sugar response to an injection of glucagon, together point toward insulin as the cause.6PubMed Central. Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia
The differential diagnosis of neonatal hypoglycemia is broad and includes other hormonal deficiencies such as panhypopituitarism, where the pituitary gland fails to produce multiple hormones including cortisol and growth hormone.7PubMed Central. Congenital hyperinsulinism and panhypopituitarism: a rare combination Inborn errors of metabolism and adrenal insufficiency can also mimic hyperinsulinism. Getting the right diagnosis early matters because the treatments are completely different.
Telling Focal From Diffuse With Imaging
Once congenital hyperinsulinism is confirmed and the baby does not respond to first-line medication, the team needs to know whether the disease is focal or diffuse before deciding on surgery. The key imaging tool is a specialized PET-CT scan using a tracer called 18F-DOPA. Insulin-producing cells concentrate this tracer, and in focal disease a single hot spot lights up on the scan, pinpointing the lesion. A meta-analysis found that 18F-DOPA PET localized focal disease with a pooled accuracy of about 80%.8PubMed. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis A study of ten children found that the integrated PET-CT accurately matched what surgeons found during the operation in nine cases, enabling a limited, curative resection.9The Journal of Clinical Endocrinology & Metabolism. Evaluation of [18F]Fluoro-l-DOPA Positron Emission Tomography-Computed Tomography for Surgery in Focal Congenital Hyperinsulinism Not every hospital offers this scan, so families may need to travel to a specialized center.
First-Line Medical Treatment
Diazoxide is the only FDA-approved medication for persistent hypoglycemia caused by hyperinsulinism and is considered first-line therapy.10The Journal of Clinical Endocrinology & Metabolism. Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism It works by opening the same potassium channels that genetic mutations have disabled, so it effectively counteracts milder channel defects and many non-channel-related forms of hyperinsulinism. A baby is considered responsive to diazoxide if blood glucose stays above about 70 mg/dL during an age-appropriate fast or if the body begins producing ketones before glucose drops below 50 mg/dL.
The drug is not without side effects. The most commonly reported one is excessive hair growth, occurring in roughly a quarter to a third of treated children. More concerning is the risk of pulmonary hypertension, an increase in blood pressure within the lungs. In one cohort of 23 neonates who received diazoxide, four developed pulmonary hypertension and one died; all affected babies had been born preterm and already had risk factors for the condition.11PubMed Central. Diazoxide for Neonatal Hyperinsulinemic Hypoglycemia and Pulmonary Hypertension Bone marrow suppression, leading to drops in white blood cell or platelet counts, has also been reported.10The Journal of Clinical Endocrinology & Metabolism. Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism Regular blood monitoring is standard practice during treatment.
Babies with the most severe channel mutations, particularly those with biallelic loss-of-function defects, are often completely unresponsive to diazoxide because the drug has no working channel to open. This group represents the greatest medical challenge.
When Diazoxide Does Not Work
For babies who fail diazoxide, clinicians turn to somatostatin analogues. Octreotide, given by subcutaneous injection or continuous infusion, can help stabilize glucose by suppressing insulin release through a different pathway. Early studies showed octreotide was useful in reducing glucose infusion needs acutely, though resistance to the drug developed over time in all patients studied, and glucose control was often inadequate to avoid surgery. Side effects included temporary malabsorption and some slowing of growth with long-term use.12PubMed. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism
A longer-acting formulation, lanreotide autogel, has shown promise. In a series of patients with severe neonatal hyperinsulinism unresponsive to diazoxide, a single injection of lanreotide raised average blood glucose and allowed physicians to stop IV glucose, octreotide, and glucagon within days. Carbohydrate requirements dropped substantially, and over a combined treatment period of more than four years, no serious adverse effects were observed.13PubMed Central. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism Lanreotide’s advantage is convenience: one injection every few weeks versus multiple daily doses of octreotide.
Surgical Options
Surgery becomes necessary when medications cannot keep a baby’s blood sugar safe. The approach depends entirely on whether the disease is focal or diffuse. For focal disease, the affected tissue is removed in a limited procedure that often takes out less than half the pancreas, sometimes as little as a few percent. Cure rates are excellent: about 97% of focal patients are cured after surgery.14PubMed Central. Surgical Treatment of Congenital Hyperinsulinism: Results from 500 Pancreatectomies in Neonates and Children These children typically go on to have normal glucose regulation and avoid the long-term consequences of major pancreatic surgery.
Diffuse disease presents a far harder situation. When the entire pancreas is overproducing insulin, surgeons have historically performed a near-total pancreatectomy, removing roughly 95–98% of the organ. Outcomes after this procedure are highly variable. Some children achieve stable blood sugar, but a substantial number still have persistent hypoglycemia afterward, and many eventually develop diabetes and problems digesting food because so little pancreatic tissue remains.15PubMed Central. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism The irony of trading one glucose problem for the opposite one is not lost on families or clinicians, and it drives much of the research into better medical alternatives.
Brain Injury From Prolonged Low Blood Sugar
The most feared complication of hyperinsulinism is brain damage from prolonged or recurrent hypoglycemia. The neonatal brain depends almost entirely on glucose for energy, and it has very limited reserves. When supply is cut off by inappropriate insulin activity, certain brain regions are particularly vulnerable. Imaging studies show that brain lesions in hyperinsulinism tend to affect the parietal and occipital lobes of the brain most severely.16European Journal of Radiology Extra. Brain injury due to persistent hyperinsulinemic hypoglycemia of infancy These regions handle sensory processing and vision, which is why some affected children develop visual impairment, learning difficulties, or epilepsy.
This pattern of injury is distinct from what happens in other causes of neonatal brain damage, like oxygen deprivation during birth, and can help radiologists identify hypoglycemia as the culprit when reviewing brain scans. The severity of injury correlates with how long and how often blood sugar drops below critical thresholds, which is why rapid diagnosis and aggressive glucose support in the first hours of life are so important.
The Long-Term Toll of Near-Total Pancreatectomy
For children who undergo near-total pancreatectomy for diffuse disease, the long-term consequences are significant. In one study following 44 children after the procedure, the rate of insulin-dependent diabetes reached 96% by eleven years after surgery. Almost three-quarters had severe exocrine pancreatic insufficiency, meaning the pancreas could no longer produce enough digestive enzymes. About half had clinical symptoms of this insufficiency, such as fatty stools and poor nutrient absorption.17PLoS ONE. Pancreatic Endocrine and Exocrine Function in Children following Near-Total Pancreatectomy for Diffuse Congenital Hyperinsulinism These children need lifelong management: insulin for diabetes, pancreatic enzyme supplements with every meal, and ongoing nutritional monitoring.
Even in the broader surgical literature beyond hyperinsulinism, pancreatectomy carries meaningful risk. Roughly one in five patients develops new or worsening diabetes after the procedure, and more than a third develops exocrine insufficiency.18PubMed Central. Long Term Endocrine and Exocrine Insufficiency after Pancreatectomy For children with diffuse hyperinsulinism, the rates are dramatically higher because so much more tissue is removed. This reality is a major reason why clinicians increasingly try to manage diffuse disease medically for as long as possible, hoping the condition attenuates with age, which it sometimes does.
Feeding Difficulties After Diagnosis
A problem that often surprises families is how hard feeding can be, both during and after treatment. About 18% of babies admitted for congenital hyperinsulinism in one prospective study were identified as having significant feeding problems, including poor sucking, vomiting, and food aversion. Nearly two-thirds of those babies needed tube feeding at diagnosis. While most improved over the first year, food aversion resolved slowly, taking an average of 240 days after discharge. A quarter of children followed for three years still reported aversion.19PubMed Central. Delayed Resolution of Feeding Problems in Patients With Congenital Hyperinsulinism
A separate study found that nearly half of children with persistent hyperinsulinism developed food aversion, and about half of those were also developmentally delayed.20PubMed. Food aversion among patients with persistent hyperinsulinemic hypoglycemia of infancy The causes are likely intertwined: repeated episodes of nausea from hypoglycemia, frequent blood draws and medical interventions, and the disruption of normal early feeding patterns by IV lines and nasogastric tubes. Speech pathology and occupational therapy input can help, but families should expect that feeding may remain a challenge well beyond the initial hospitalization.
Maintaining enteral feeding alongside IV glucose support, rather than withholding feeds entirely, appears to help. One study found that hypoglycemic infants who continued to feed while receiving IV dextrose needed the IV for a shorter period and had fewer further drops in blood sugar compared with those who were kept from eating.21PubMed Central. Continued Enteral Feeding Is Beneficial in Hypoglycemic Infants Admitted to Intensive Care for Parenteral Dextrose Therapy
The Burden on Families
Living with a baby who has congenital hyperinsulinism is relentless. Families face the constant need to measure blood sugar levels, the anxiety of knowing that a missed low could harm their child’s brain, and the exhausting schedule of frequent feedings, sometimes every two to three hours around the clock. Surveys of affected families document substantial stress and anxiety related to the fear of hypoglycemia and the demands of ongoing monitoring.22PubMed Central. Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
The financial burden is also real. Transient hyperinsulinism alone leads to longer and costlier hospital stays compared with other forms of neonatal hypoglycemia.23PubMed. Transient neonatal hyperinsulinaemic hypoglycaemia: perinatal predictors of length and cost of stay For severe congenital forms, costs are even more concentrated: in a UK study, fewer than 6% of patients, almost all in their first year of life, accounted for more than 60% of total healthcare costs for the condition.24PubMed Central. The burden of congenital hyperinsulinism in the United Kingdom: a cost of illness study These figures do not capture the indirect costs of lost parental income, travel to specialized centers, or the ongoing expenses of glucose monitoring supplies and medications.
Experimental Treatments on the Horizon
For children with diazoxide-unresponsive disease, researchers are exploring several new angles. One of the most studied is exendin-(9-39), a compound that blocks the receptor for GLP-1, a gut hormone that normally amplifies insulin release after eating. In clinical trials, infusing exendin-(9-39) significantly raised fasting blood glucose levels and lowered insulin-to-glucose ratios in children with channel-related hyperinsulinism.25PubMed Central. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel Follow-up work showed that the compound also prevented hypoglycemia after meals and protein challenges, broadening its potential usefulness.26PubMed Central. Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge The effect has not been complete enough for monotherapy, but researchers see potential for combining it with existing drugs to reduce or eliminate the need for surgery.
Another avenue involves mTOR inhibitors, drugs already used in transplant medicine and certain cancers. Sirolimus has been used successfully in small numbers of patients with diazoxide-unresponsive congenital hyperinsulinism, working through a pathway that influences the growth and activity of insulin-producing cells.27Annals of Pediatric Endocrinology & Metabolism. Congenital hyperinsulinism: current status and future perspectives Its long-term safety in infants is still being evaluated, and it remains far from routine use, but it represents one more option for families running out of alternatives. The overarching goal of all this research is to give children with diffuse disease a way to keep their pancreas and avoid the cascade of lifelong complications that near-total pancreatectomy brings.